Key result
Injectable therapies for chronic conditions face patient-reported barriers like fear of needles and social stigma, alongside facilitators like health improvement, across 20 reviewed studies.
Why the study?
Translating evidence-based injectable treatments into real-world practice remains challenging despite advances in drug development and device innovation.
What are the patient-reported facilitators, barriers, and perceptions regarding the delivery and management of injectable therapies in chronic conditions?
What are the patient-reported facilitators, barriers, and perceptions regarding the delivery and management of injectable therapies in chronic conditions?
Understanding patient-reported facilitators and barriers to injectable therapies is crucial for improving communication, shared decision-making, and self-management support in chronic cardiovascular care.
Clinicians should address needle fear and stigma in injectable counseling; extends patient-centered evidence guiding shared decisions in chronic cardiovascular care.
INTRODUCTION: Although preventive health and therapeutics have benefited from advances in drug development and device innovation, translating these evidence-based treatments into real-world practice remains challenging. AIM: The current integrative review aims to identify facilitators and barriers and perceptions in delivering and managing injectable therapies from patient perspectives. METHODS: An integrative review was conducted in the databases of PubMed, CINAHL, PsycINFO and Cochrane. Keywords were used "Injectable therapy", "IV therapy", "SC therapy", "long term injectable therapies", "self-administered injectable therapy", "patients", "caregivers", "family", "carers", "facilitators", "barriers", "perspectives", "needs", "expectations", "chronic disease", "cardiovascular disease" linked with the words "OR" and "AND". The search was limited from January 2000 to July 2019. Inclusion and exclusion criteria were used. RESULTS: Twenty studies were identified from the literature search. Studies followed qualitative, quantitative methodology and mixed methods. Facilitators included: health improvement, prevention of disease complications, taking control of their disease, effectiveness of the medication and convenience in management. Barriers included: fear of needles, insulin will cause harm, poor perception of the benefits of injectable therapies on their quality of life, inconvenience in self-management, social stigma, impact on daily living, financial barriers, lack of education. Perceptions included: 'treatment of last resort', 'life becomes less flexible', 'injectables were punishment/restriction', 'personal failure of self-management'. CONCLUSION: Evidence shows how to create effective communication and shared decision-making relationships to provide best possible care to patients who need injectable therapy and support for self-management. Future research might help guide response to the fears and barriers of the patients using patients' perspectives.
No takes yet. Share an insight, caveat, or question.
Lambrinou et al. (2020) conducted a review in Chronic conditions (n=20). Injectable therapies was evaluated on Facilitators, barriers, and perceptions in delivering and managing injectable therapies. Injectable therapies for chronic conditions face patient-reported barriers like fear of needles and social stigma, alongside facilitators like health improvement, across 20 reviewed studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: